


# 重组抗体,抗VSV-M [23H12],人,IgG1K

[下载为PDF](#)

- 8 次围观

产品图片



产品英文名称

[Recombinant Anti-VSV-M \[23H12\], Human, IgG1k](#)

产品别名

[Kerafast独特的生物试剂](#)

货号/SKU

Kf-Ab01404-10.0

货号/规格

200ug

库存与交货期

1-2周

人民币价格

11350

人民币价格说明

本产品人民币2024年销售价格正在调整中，请等待更新完毕。

本商品的展示的人民币价格已包含商品本身金额、VAT增值税13%、国际运输运费、国内物流运费、运输保险、以及冷链包装材料（例如液氮罐、泡沫箱、金属桶、蓝冰、湿冰、干冰、蓄冷剂、液氮等）、装卸费、相关资料费、人力支出等一切费用。

本商品的美元价、市场价、零售价、厂商指导价或该商品的曾经展示过的销售价等，并非商品原价，仅供参考。

试剂海关审批

使用人负责A/B风险申请资质

国外采购

支持/部分需签MTA

厂牌

Kerafast, Inc.

品牌

[Kerafast®](#)

产品基础信息

From the laboratory of Douglas S. Lyles, PhD, Wake Forest School of Medicine.

产品描述信息

Product Type:

Antibody

Name: Anti-VSV-M [23H12]  
 Antigen: VSV-M  
 Host: Mouse  
 Isotype: **EB0011:** IgG2a kappa  
**Recombinant versions:** see product name  
 Clonality: Monoclonal  
 Clone Name: 23H12  
 Specificity: VSV-Ind matrix (M) protein  
 Reactivity: Human  
 Immunogen: VSV infection  
 Format: Liquid  
 Purity: Protein G purified  
 Buffer: **EB0011:** PBS, 0.05% (w/v) Sodium Azide  
**Recombinant versions:** PBS with 0.02% Proclin 300  
 Tested Applications: Western blot (1:1000)  
 Concentration: 1mg/mL  
 Amount: 100uL  
 Storage: -20C (avoid repeated freeze / thaw cycles)  
 Shipped: Cold packs

#### 产品信息

Lyles DS, Puddington L, McCreedy BJ Jr. Vesicular stomatitis virus M protein in the nuclei of infected cells. *J Virol.* 1988 Nov;62(11):4387-92. PubMed PMID: 2845149  
 Lefrancios L, Lyles DS. The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies. *Virology* 121: 157-167, 1982.  
 Marcos-Villar L, Pérez-Girón JV, Vilas JM, Soto A, de la Cruz-Herrera CF, Lang V, Collado M, Vidal A, Rodríguez MS, Muñoz-Fontela C, Rivas C. SUMOylation of p53 mediates interferon activities. *Cell Cycle.* 2013 Sep 1;12(17):2809-16. View Article  
 de la Cruz-Herrera CF, Campagna M, García MA, Marcos-Villar L, Lang V, Baz-Martínez M, Gutiérrez S, Vidal A, Rodríguez MS, Esteban M, Rivas C. Activation of the double-stranded RNA-dependent protein kinase PKR by small ubiquitin-like modifier (SUMO). *J Biol Chem.* 2014 Sep 19;289(38):26357-67. View Article  
 Hoffmann M, Krüger N, Zmora P, Wrensch F, Herrler G, Pöhlmann S. The Hemagglutinin of Bat-Associated Influenza Viruses Is Activated by TMPRSS2 for pH-Dependent Entry into Bat but Not Human Cells. *PLoS One.* 2016 Mar 30;11(3):e0152134.  
 Salata C, Baritussio A, Munegato D, Calistri A, Ha HR, Bigler L, Fabris F, Parolin C, Palù G, Mirazimi A. Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process. *Pathog Dis.* 2015 Jul;73(5). pii: ftv032. View Article  
 Plegge T, Hofmann-Winkler H, Spiegel M, Pöhlmann S. Evidence that Processing of the Severe Fever with Thrombocytopenia Syndrome Virus Gn/Gc Polyprotein Is Critical for Viral Infectivity and Requires an Internal Gc Signal Peptide. *PLoS One.* 2016 Nov 17;11(11):e0166013. View Article  
 Baz-Martínez M, Da Silva-Álvarez S, Rodríguez E, Guerra J, El Motiam A, Vidal A, García-Caballero T, González-Barcia M, Sánchez L, Muñoz-Fontela C, Collado M, Rivas C. Cell senescence is an antiviral defense mechanism. *Sci Rep.* 2016 Nov 16;6:37007. View Article  
 Wrensch F, Hoffmann M, Gärtner S, Nehlmeier I, Winkler M, Pöhlmann S. Virion background and efficiency of virion incorporation determine susceptibility of SIV-Env-driven viral entry to inhibition by IFITM proteins. *J Virol.* 2016 Nov 2. pii: JVI.01488-16. View Article  
 Hsu HL, Millet JK, Costello DA, Whittaker GR, Daniel S. Viral fusion efficacy of specific H3N2 influenza virus reassortant combinations at single-particle level. *Sci Rep.* 2016 Oct 18;6:35537. View Article  
 Pirooz SD, He S, Zhang T, Zhang X, Zhao Z, Oh S, O'Connell D, Khalilzadeh P, Amini-Bavil-Olyaei S, Farzan M, Liang C. UVRAG is required for virus entry through combinatorial interaction with the class C-Vps complex and SNAREs. *Proc Natl Acad Sci U S A.* 2014 Feb 18;111(7):2716-21. View Article  
 Salata C, Baritussio A, Munegato D, Calistri A, Ha HR, Bigler L, Fabris F, Parolin C, Palù G, Mirazimi A. Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process. *Pathog Dis.* 2015 Jul;73(5). View Article  
 González-Santamaría J, Campagna M, Ortega-Molina A, Marcos-Villar L, de la Cruz-Herrera CF, González D, Gallego P, Lopitz-Otsoa F, Esteban M, Rodríguez MS, Serrano M, Rivas C. Regulation of the tumor suppressor PTEN by SUMO. *Cell Death Dis.* 2012 Sep 27;3:e393. doi: 10.1038/cddis.2012.135. PubMed PMID: 23013792; PubMed Central PMCID: PMC3461367. View Article  
 Ueda MT, Kurosaki Y, Izumi T, Nakano Y, Oloniniyi OK, Yasuda J, Koyanagi Y, Sato K, Nakagawa S. Functional mutations in spike glycoprotein of Zaire ebolavirus associated with an increase in infection efficiency. *Genes Cells.* 2017 Feb;22(2):148-159. doi: 10.1111/gtc.12463. PubMed PMID: 28084671. View Article  
 Hoffmann M, Crone L, Dietzel E, Paijo J, González-Hernández M, Nehlmeier I, Kalinke U, Becker S, Pöhlmann S. A polymorphism within the internal fusion loop of the Ebola virus glycoprotein modulates host cell entry. *J Virol.* 2017 Feb 22. pii: JVI.00177-17. doi: 10.1128/JVI.00177-17. [Epub ahead of print] PubMed PMID: 28228590. View Article  
 Hofmann H, Li X, Zhang X, Liu W, Kühl A, Kaup F, Soldan SS, González-Scarano F, Weber F, He Y, Pöhlmann S. Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines. *J Virol.* 2013 Apr;87(8):4384-94. doi: 10.1128/JVI.02628-12. Epub 2013 Feb 6. PubMed PMID: 23388721; PubMed Central PMCID: PMC3624395. View Article  
 de la Cruz-Herrera CF, Baz-Martínez M, Motiam AE,

Vidal S, Collado M, Vidal A, Rodríguez MS, Esteban M, Rivas C. Phosphorylable tyrosine residue 162 in the double-stranded RNA-dependent kinase PKR modulates its interaction with SUMO. *Sci Rep.* 2017 Oct 25;7(1):14055. View Article

Brinkmann C, Hoffmann M, Lübke A, Nehlmeier I, Krämer-Kühl A, Winkler M, Pöhlmann S. The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells. *PLoS One.* 2017 Dec 7;12(12):e0189073. View Article

Acciani M, Alston JT, Zhao G, Reynolds H, Ali AM, Xu B, Brindley MA. Mutational Analysis of Lassa Virus Glycoprotein Highlights Regions Required for Alpha-Dystroglycan Utilization. *J Virol.* 2017 Aug 24;91(18). pii: e00574-17. View Article

Kurosaki Y, Ueda MT, Nakano Y, Yasuda J, Koyanagi Y, Sato K, Nakagawa S. Different effects of two mutations on the infectivity of Ebola virus glycoprotein in nine mammalian species. *J Gen Virol.* 2018 Feb;99(2):181-186. View Article

Emanuel J, Callison J, Dowd KA, Pierson TC, Feldmann H, Marzi A. A VSV-based Zika virus vaccine protects mice from lethal challenge. *Sci Rep.* 2018 Jul 23;8(1):11043. View Article

Kleine-Weber H, Elzayat MT, Hoffmann M, Pöhlmann S. Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein. *Sci Rep.* 2018 Nov 9;8(1):16597. View Article

Locher S, Schweneker M, Hausmann J, Zimmer G. Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs. *J Gen Virol.* 2018 Jul;99(7):866-879. doi: 10.1099/jgv.0.001085. Epub 2018 Jun 5. View Article

González-Hernández M, Hoffmann M, Brinkmann C, Nehls J, Winkler M, Schindler M, Pöhlmann S. A GXXXA Motif in the Transmembrane Domain of the Ebola Virus Glycoprotein Is Required for Tetherin Antagonism. *J Virol.* 2018 Jun 13;92(13). pii: e00403-18. View Article

Abdullahi S, Jäkel M, Behrend SJ, Steiger K, Topping G, Krabbe T, Colombo A, Sandig V, Schiergens TS, Thasler WE, Werner J, Lichtenthaler SF, Schmid RM, Ebert O, Altomonte J. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma. *J Virol.* 2018 Nov 12;92(23). pii: e01386-18. View Article

Orzalli MH, Smith A, Jurado KA, Iwasaki A, Garlick JA, Kagan JC. An Antiviral Branch of the IL-1 Signaling Pathway Restricts Immune-Evasive Virus Replication. *Mol Cell.* 2018 Sep 6;71(5):825-840.e6. doi: 10.1016/j.molcel.2018.07.009. Epub 2018 Aug 9. View Article

Kleine-Weber H, Elzayat MT, Wang L, Graham BS, Müller MA, Drosten C, Pöhlmann S, Hoffmann M. Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization. *J Virol.* 2019 Jan 4;93(2). View Article

Hoffmann M, Kaufmann SV, Fischer C, Maurer W, Moldenhauer AS, Pöhlmann S. Analysis of Resistance of Ebola Virus Glycoprotein-Driven Entry Against MDL28170, An Inhibitor of Cysteine Cathepsins. *Pathogens.* 2019;8(4):192. Published 2019 Oct 15. View article

Kleine-Weber H, Pöhlmann S, Hoffmann M. Spike proteins of novel MERS-coronavirus isolates from North- and West-African dromedary camels mediate robust viral entry into human target cells. *Virology.* 2019;535:261-265. View article

Furuyama W, Reynolds P, Haddock E, et al. A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades. *NPJ Vaccines.* 2020;5:4. Published 2020 Jan 10. View article

Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol.* 2020;5(4):562-569. View article

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell.* 2020;181(2):271-280.e8. View article

Hoffmann M, Kleine-Weber H, Pöhlmann S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol Cell.* 2020;78(4):779-784.e5. View article

Wells HL, Letko M, Lasso G, et al. The evolutionary history of ACE2 usage within the coronavirus subgenus Sarbecovirus. Preprint. *bioRxiv.* 2020;2020.07.07.190546. Published 2020 Jul 7. View article

Liberatore RA, Mastrocola EJ, Cassella E, Schmidt F, Willen JR, Voronin D, Zang TM, Hatzioannou T, Bieniasz PD. Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection. *Elife.* 2019 Oct 23;8:e49875. View article

Korzyukov Y, Iheozor-Ejiofor R, Levanov L, Smura T, Hetzel U, Szivovics L, de la Torre JC, Martinez-Sobrido L, Kipar A, Vapalahti O, Hepojoki J. Differences in Tissue and Species Tropism of Reptarenavirus Species Studied by Vesicular Stomatitis Virus Pseudotypes. *Viruses.* 2020 Apr 2;12(4):395. View article

Pryce R, Azarm K, Rissanen I, Harlos K, Bowden TA, Lee B. A key region of molecular specificity orchestrates unique ephrin-B1 utilization by Cedar virus. *Life Sci Alliance.* 2019 Dec 20;3(1):e201900578. View article

Oguntuyo KY, Stevens CS, Hung CT, Ikegame S, Acklin JA, Kowdle SS, Carmichael JC, Chiu HP, Azarm KD, Haas GD, Amanat F, Klingler J, Baine I, Arinsburg S, Bandres JC, Siddiquey MN, Schilke RM, Woolard MD, Zhang H, Duty AJ, Kraus TA, Moran TM, Tortorella D, Lim JK, Gamarnik AV, Hioe CE, Zolla-Pazner S, Ivanov SS, Kamil JP, Krammer F, Lee B. Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera. *medRxiv [Preprint].* 2020 Aug 15:2020.08.13.20157222. View Article

Condor Capcha JM, Lambert G, Dykxhoorn DM, Salerno AG, Hare JM, Whitt MA, Pahwa S, Jayaweera DT, Shehadeh LA. Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral Entry and Neutralization Assays: A 1-Week Protocol. *Front Cardiovasc Med.* 2021 Jan 15;7:618651. View article

Furuyama W, Shifflett K, Pinski AN, Griffin AJ, Feldmann F, Okumura A, Gourdine T, Jankeel A, Lovaglio J, Hanley PW, Thomas T, Clancy CS, Messaoudi I, O'Donnell KL, Marzi A. Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine. *bioRxiv [Preprint].* 2021 Jan 19:2021.01.19.426885. View article

Li W, Chen C, Drelich A, Martinez DR, Gralinski LE, Sun Z, Schäfer A, Kulkarni SS, Liu X, Leist SR, Zhelev DV, Zhang L, Kim YJ, Peterson EC, Conard A, Mellors JW, Tseng CK, Falzarano D, Baric RS, Dimitrov DS. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. *Proc Natl Acad Sci U S A.* 2020 Nov 24;117(47):29832-29838. View article

Hoffmann M, Zhang L, Krüger N, Graichen L, Kleine-Weber H, Hofmann-Winkler H, Kempf A, Nessler S, Riggert J, Winkler MS, Schulz S, Jäck HM,

Pöhlmann S. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Rep. 2021 Apr 20;35(3):109017. View article if you publish research with this product, please let us know so we can cite your paper.

#### 主要内容

该单克隆抗体与VSV-M蛋白反应。高灯：与我们姐妹公司的免疫印迹应用特征版本的VSV-M蛋白质，绝对抗体和来自杂交瘤的可变区（即特异性）制造的蛋白质印迹应用特征版本反应口腔炎病毒（VSV）是一种良好的研究，包膜，阴茎RNA病毒。对于5个蛋白质的VSV基因组编码：N，P，M，G和L.g蛋白（糖蛋白）位于病毒米氏菌表面，并负责病毒附着和渗透。另外，许多慢病毒载体与来自印第安纳血清型的VSV-G具有假型。静脉炎病毒（VSV）是一种良好的研究，包膜，阴茎RNA病毒。对于5个蛋白质的VSV基因组编码：N，P，M，G和L. M蛋白（或基质蛋白）负责将核衣壳结合并将其冷凝成紧密卷曲的螺旋并将核衣壳结合到包络中。这种M蛋白的这种活性是给病毒它的子弹状况。除了M蛋白在病毒组件中的作用外，还负责介导VSV发病机制的分子机制。野生型M蛋白在感染细胞中捕获宿主基因表达，抑制抗病毒反应。通过Degouglas S. Lyles, Phd, Wake Forest医学院的实验室。

#### 厂牌介绍

### 关于Kerafast Inc.

Kerafast 是一家位于波士顿的试剂公司，其主要使命是为QuanQiu科学界提供易于使用的独特实验室研究工具。我们的产品组合包括细胞系、抗体、小分子、染料等，其中许多在其他地方无法获得。自2011年成立以来，来自[全球190多个机构](#)的研究人员通过我们的在线平台提供了他们的创新试剂，无需通过传统的材料转让协议流程即可快速获取材料。

我们处理提供实验室的所有销售和运输物流，并从每次销售中返还丰厚的特许权使用费。因此，我们帮助提供实验室节省时间和资源，同时为进一步研究提供额外资金。采购科学家可以更轻松地发现和获取其他地方通常无法获得的独特试剂，同时还可以资助其他研究人员的工作。这创建了一个QuanQiu科学家社区，他们贡献和获取Reagent for the Greater Good，以加速他们自己的研究以及整体科学进步。

2018年，Kerafast与[Absolute Antibody](#)合并，后者是一家总部位于英国的公司，其愿景是为所有研究人员提供重组抗体技术。[此次合并](#)将两家公司聚集在一起，共同致力于改善科学界可用的研究工具的选择。

#### 品牌标识



#### 产品关键词

- [kerafast抗体ED2003](#)
- [kerafast 抗体](#)
- [kerafast国内代理商](#)
- [kerafast](#)
- [kerafast 代理](#)
- [kerafast细胞](#)
- [kerafast抗体代理](#)
- [kerafast代理商](#)
- [kerafast品牌](#)
- [kerafast代理](#)
- [kerafast细胞代购kerafast品牌代理](#)
- [kerafast华北代理](#)
- [美国kerafast公司](#)
- [kerafast公司](#)
- [进口kerafast代理](#)
- [kerafast工香通](#)
- [kerafast中国代理](#)
- [kerafast官网](#)
- [kerafast抗体](#)
- [kerafast专业代理](#)

一键获取大包装优惠报价

#### 选择您的报价场景

- 【我们直接使用】需要优惠报价、大包装规格、货期 -- ---->[报价默认含增值税13%发票；尽量提供货号、规格、需求数量]
- 【需要技术文档】产品说明书、COA、MSDS、手册 -- ---->[默认提供说明书或者COA，特别技术指标要求请下面填入详细描述]
- 【我帮客户找货】需要优惠报价、大包装规格、货期 -- ---->[报价默认含增值税13%发票]
- 【推荐替代产品】需要优惠报价、大包装规格、货期 -- ---->[提供替代产品的价格，默认含增值税13%发票]
- 【我能原厂直采】请只提供代理进口清关服务的报价 -- ---->[适合只需要进口许可证代办服务、清关服务的专业级买家，独立服务]
- 【其它报价场景】

请输入您的情况与报价要求

请输入您的情况与报价要求

#### 报价要求详细描述


【如有请填写;若无留空即可】按10KG、25L大量采购的时候, 是否可

贵单位贵姓 请输入您的单位名称或贵姓, 以便于我们联系您

接受报价的E-mail 请输入您接受报价单的E-mail, 例如:example@qq.com

马上发我报价

## 手机扫描二维码阅读本页



## 可能感兴趣的内容

[心衰进程中非编码RNA对线粒体功能的调控作用](#)

2023-07-18

[B淋巴细胞高通量筛选系统Cyto-Mine](#)

2019-06-24

[人工肺粘液-BZ365](#)

2024-08-16

[NR-15893重组鼠疫\(鼠疫耶尔森氏菌\)疫苗\(抗原制剂\)](#)

2022-04-01

[升级版SBF-r-SBF模拟体液-BZ332](#)

2024-08-16

[NR-47621金黄色葡萄球菌亚种.金黄色葡萄球菌、J2、转座子突变体NE1078\(SAUSA300\\_1698\)\(突变细菌\)](#)

2022-04-01

[FAM炔炔,5个异构体,10毫克](#)

2021-12-21

[NR-52507来自SARS相关冠状病毒2的基因组RNA,分离物USA-CA3/2020\(核酸\)](#)

2022-04-01

[NR-51292土拉弗朗西斯菌亚种.novicida,“双等位基因”转座子突变库,板10\(tnfn1\\_pw060328p02\)\(突变细菌\)](#)

2022-04-01

[抗体片段在铂纳米粒子表面的构象重构](#)

2024-03-25

[抗白貂B细胞,轻链\(Ig Kappa\)\[4-E3\]抗体,100ug](#)

2021-12-21

[免疫球蛋白\\_G2\\_\(IgG2\)\\_人骨髓瘤血浆来源提纯](#)

2022-03-22

[NR-53822肽阵列,SARS冠状病毒膜\(M\)蛋白\(肽和肽阵列\)](#)

2022-04-01

[抗BCL2相关转录因子1\(BCLAF-1\)\[M33P5B11\]抗体](#)

2021-12-21

[PCAG-P65AD-GBP6质粒](#)

2021-12-21

[NR-768牛痘病毒,单克隆抗牛痘\(WR\)B5R,残基20至275,胞外域\(腹水\)\(类似于VMC-25\)\(单克隆抗体\)](#)

2022-03-31

[NR-19027结核分枝杆菌,HN4048\(细菌\)](#)

2022-04-01

[微米粉体\(Pr\)溅射靶材,纯度:99.9%,Size:8",厚:0.125"](#)

2024-01-21

[狗\(混合品种\) - 睾丸 - 石蜡嵌入式组织块\(PETB\)](#)

2021-12-21

[抗补体C3 \[8E11\]抗体](#)

2021-12-21